AngiosarcomaSymptoms, Doctors, Treatments, Advances & More
Learn About Angiosarcoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Advocate Lutheran General Cancer Institute
Pamela Kaiser is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. Kaiser is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endoscopy. Dr. Kaiser is board certified in American Board Of Internal Medicine, Medical Oncology.
Advocate Christ Outpatient Pavilion Breast Surgery
Barbara Krueger is a General Surgeon practicing medicine in Oak Lawn, Illinois. Dr. Krueger is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy. Dr. Krueger is board certified in American Board Of Surgery.
Lutheran General Caldwell Breast Center
Anna Katz is a General Surgeon and a Surgical Oncologist practicing medicine in Park Ridge, Illinois. Dr. Katz is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy. Dr. Katz is board certified in American Board Of Surgery.
Summary: This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute ...
Summary: This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.